## CI: The Cigna Group - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.55 indicates fundamental undervaluation. Quality metrics strong (ROE 16%). Consistent execution (3/4 quarters beat estimates).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($261.59)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 9
- **Sentiment:** Neutral (Bullish: 2, Bearish: 1)

**1. ATTENTION CI SHAREHOLDERS: Investors Who Lost Money on The Cigna Group are Urged to Contact Levi & Korsinsky About an Ongoing Investigation**
- Source: WJTV | 20251217T120752 | Bearish | Relevance: 100%
- Levi & Korsinsky has initiated an investigation into The Cigna Group (NYSE:CI) concerning potential violations of federal securities laws. This follows Cigna's Q3 2025 earnings report, which revealed a higher Healthcare Medical Care Ratio (MCR) of 84.8% compared to 82.8% in Q3 2024, leading to a significant drop in the company's stock price by 17% on October 30, 2025. Investors who suffered losses are encouraged to contact Levi & Korsinsky for more information regarding the ongoing investigation.

**2. Does Cigna Group’s Recent Gains Reflect Its Long Term Potential In 2025?**
- Source: Simply Wall Street | 20251217T010759 | Bullish | Relevance: 100%
- This article analyzes Cigna Group (NYSE: CI) to determine if its current stock price reflects its long-term potential, suggesting it might be undervalued. Using a Discounted Cash Flow (DCF) analysis, the intrinsic value is estimated at $1,062 per share, indicating a significant 74.0% discount. Additionally, its current Price-to-Earnings (PE) ratio of 12.0x is well below industry averages, further supporting the undervaluation thesis based on its Fair Ratio framework.

**3. Does Cigna Group’s Recent Gains Reflect Its Long Term Potential In 2025?**
- Source: Simply Wall Street | 20251217T012346 | Bullish | Relevance: 100%
- Cigna Group (NYSE:CI) is currently trading at what appears to be a significant discount, with a valuation score of 5/6 and a potential 74.0% undervaluation based on discounted cash flow analysis. The stock also trades at a lower Price/Earnings ratio (12.0x) compared to the broader healthcare industry (23.9x) and its peer group (31.2x), suggesting it is undervalued given its earnings growth outlook. Investors can explore "Narratives" on Simply Wall St to understand different assumptions influencing Cigna's fair value.

**4. Rep. Julie Johnson Sells Off Shares of Analog Devices, Inc. (NASDAQ:ADI)**
- Source: MarketBeat | 20251216T080821 | Neutral | Relevance: 74%
- Representative Julie Johnson (D-Texas) recently sold between $1,001 and $15,000 worth of Analog Devices (NASDAQ:ADI) stock on November 13th, along with similar-sized sales in several other companies. This occurred after Analog Devices reported strong quarterly earnings, declared a dividend, and despite a "Moderate Buy" consensus rating from analysts. Insider selling by the CEO and a director was also noted.

**5. Rep. Julie Johnson Sells Medtronic PLC (NYSE:MDT) Stock**
- Source: MarketBeat | 20251216T080858 | Neutral | Relevance: 74%
- Representative Julie Johnson (D-Texas) recently sold between $1,001 and $15,000 worth of Medtronic PLC (NYSE:MDT) stock on November 13th, along with similar-sized sales from other large-cap companies. This sale occurred while Medtronic reported strong quarterly earnings, beating expectations with an EPS of $1.36 and revenue of $8.96 billion, and declared a $0.71 quarterly dividend. Institutional investors hold approximately 82% of MDT stock, and analysts maintain a "Moderate Buy" rating with an average target price of $110.44.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 2 ($1.01M) |
| Sells | 2 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 48.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 9.6% (+0.1%)
- Blackrock Inc.: 8.3% (-1.1%)
- JPMORGAN CHASE & CO: 5.0% (+106.4%)
- State Street Corpora: 4.5% (-1.2%)
- Price (T.Rowe) Assoc: 4.2% (+9.8%)

### Key Risks

1. Long-term trend broken: trading 9.3% below SMA200.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.55 indicates undervaluation relative to growth. Forward P/E 9.0x stretched relative to 3% growth. Balance sheet: $3.1B free cash flow. Insider buying signal ($1.0M), management confidence. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $73.2B |
| Beta | 0.26 |
| 52W Range | $239.51 - $350.00 |
| Short Interest | 1.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.55 |
| Forward P/E | 9.0 |
| Current P/E | 9.3 |
| YoY Growth | 3.3% |
| EPS Direction | STABLE |

### Technicals

MRS_20 stable at 1.6% (minimal 5-day change). Below STRENGTH zone by 2.4pp (needs >4.0% for momentum thesis). MRS_5 (-0.4%) diverging from MRS_20 - short-term weakness emerging. Below SMA200 (0.91x), long-term trend not supportive. MACD histogram positive (1.21), confirming momentum. RSI neutral at 51. OFD pattern: +SBN (Volatile).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 1.64% (CS: 56) | Neutral |
| RSI_14 | 51.0 | Neutral |
| MACD Histogram | 1.21 | Bullish |
| vs SMA20 | 1.007x | Above |
| vs SMA50 | 0.984x | Below |
| vs SMA200 | 0.907x | Below |

### Decision

- **Verdict:** HOLD
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $273.97
- **Stop Loss:** $261.59 (4.5% risk)
- **Target:** $298.73 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 76
- **Position Value:** $20,821.72
- **Portfolio %:** 20.82%
- **Risk Dollars:** $950.00
- **Risk Per Trade:** 0.95%
- **Modifiers:** L1 95% | L2 100% | Combined 0.95x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with cautious positioning ahead of CPI data. VIX at moderate 16.87 with positive yield curve suggesting stable growth, but narrow breadth at 51.8% indicates selective participation. Banking sector optimism and corporate resilience provide support, though AI volatility creates pockets of uncertainty.*

### Earnings

**Next:** 2026-02-05 (Est: $7.90)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $7.64 | $7.83 | +2.5% |
| 2025Q2 | $7.15 | $7.20 | +0.6% |
| 2025Q1 | $6.35 | $6.74 | +6.2% |
| 2024Q4 | $7.82 | $6.64 | -15.1% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*